JP2016512564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512564A5 JP2016512564A5 JP2016502000A JP2016502000A JP2016512564A5 JP 2016512564 A5 JP2016512564 A5 JP 2016512564A5 JP 2016502000 A JP2016502000 A JP 2016502000A JP 2016502000 A JP2016502000 A JP 2016502000A JP 2016512564 A5 JP2016512564 A5 JP 2016512564A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- probenecid
- improved
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims 6
- 229960003081 probenecid Drugs 0.000 claims 6
- 210000002966 serum Anatomy 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 230000000717 retained effect Effects 0.000 claims 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 230000001882 diuretic effect Effects 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 238000010606 normalization Methods 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778826P | 2013-03-13 | 2013-03-13 | |
| US61/778,826 | 2013-03-13 | ||
| PCT/US2014/025930 WO2014160153A1 (en) | 2013-03-13 | 2014-03-13 | Treatment of a diastolic cardiac dysfunction with a trpv2 receptor agonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020203311A Division JP2021042248A (ja) | 2013-03-13 | 2020-12-08 | Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512564A JP2016512564A (ja) | 2016-04-28 |
| JP2016512564A5 true JP2016512564A5 (enExample) | 2017-06-01 |
Family
ID=50680137
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502000A Pending JP2016512564A (ja) | 2013-03-13 | 2014-03-13 | Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 |
| JP2020203311A Pending JP2021042248A (ja) | 2013-03-13 | 2020-12-08 | Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 |
| JP2023196822A Pending JP2024009140A (ja) | 2013-03-13 | 2023-11-20 | Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020203311A Pending JP2021042248A (ja) | 2013-03-13 | 2020-12-08 | Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 |
| JP2023196822A Pending JP2024009140A (ja) | 2013-03-13 | 2023-11-20 | Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10583103B2 (enExample) |
| EP (1) | EP2968238A1 (enExample) |
| JP (3) | JP2016512564A (enExample) |
| AU (1) | AU2014244053B2 (enExample) |
| CA (1) | CA2904671C (enExample) |
| MX (1) | MX376077B (enExample) |
| WO (1) | WO2014160153A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| JP6433896B2 (ja) | 2012-08-13 | 2018-12-05 | シーダーズ−サイナイ・メディカル・センターＣｅｄａｒｓ−Ｓｉｎａｉ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ | 組織再生のためのエキソソームおよびマイクロリボ核酸 |
| EP3200808B1 (en) | 2014-10-03 | 2024-07-31 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| US11253551B2 (en) | 2016-01-11 | 2022-02-22 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
| EP3515459A4 (en) | 2016-09-20 | 2020-08-05 | Cedars-Sinai Medical Center | CELLS DERIVED FROM CARDIOSPHERES AND THEIR EXTRACELLULAR VESICLES TO DELAY OR REVERSE AGING AND AGE-RELATED DISORDERS |
| EP3612191A4 (en) | 2017-04-19 | 2020-12-30 | Cedars-Sinai Medical Center | METHODS AND COMPOSITIONS FOR TREATING SKELETAL MUSCLE DYSTROPHY |
| AU2018384096B2 (en) * | 2017-12-12 | 2021-04-15 | Cardiol Therapeutics Inc. | Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure |
| US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| WO2019152549A1 (en) | 2018-02-05 | 2019-08-08 | Cedars-Sinai Medical Center | Methods for therapeutic use of exosomes and y-rnas |
| CN114945360A (zh) * | 2019-10-25 | 2022-08-26 | 心脏治疗公司 | 用于治疗心脏病的大麻二酚组合物 |
| CA3171890A1 (en) * | 2020-02-19 | 2021-08-26 | DR. MERCHANT, Shreema | Compositions and therapeutic uses of cannabidiol |
| KR20210150011A (ko) * | 2020-06-03 | 2021-12-10 | 주식회사 삼오파마켐 | 프로베네시드 및 아르기닌의 아미드 유도체, 이를 포함하는 약제학적 조성물 및 이의 제조 방법 |
| CN113861633B (zh) * | 2021-10-14 | 2022-12-20 | 武汉工程大学 | 一种p-n-b阻燃pbs塑料及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3524917A (en) | 1969-02-10 | 1970-08-18 | Merck & Co Inc | Tablets of magnesium probenecid tetrahydrate |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| JPH01211582A (ja) | 1988-02-16 | 1989-08-24 | Tanabe Seiyaku Co Ltd | ベンゾジオキソール誘導体 |
| CA2115442C (en) | 1991-09-09 | 2003-09-23 | Christopher Franklin Bigge | Pharmaceutical preparation containing an uricosuric agent and an excitatory amino acid antagonist |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| US20030212123A1 (en) | 1997-05-05 | 2003-11-13 | Pfizer Inc. | COX-2 selective carprofen for treating pain and inflammation in dogs |
| US6221856B1 (en) | 1999-02-03 | 2001-04-24 | Inologic, Inc. | Inositol derivatives for inhibiting superoxide anion production |
| ATE422357T1 (de) | 2000-06-28 | 2009-02-15 | Merck & Co Inc | Verwendung von allopurinol zur behandlung von bluthochdruck |
| AU2001227030A1 (en) | 2000-11-22 | 2002-06-03 | Lupin Laboratories Limited | Pharmaceutical composition for controlled release of an active ingredient |
| DE10064997A1 (de) | 2000-12-23 | 2002-06-27 | Merck Patent Gmbh | Benzoylpyridazine |
| US20080051428A1 (en) | 2002-05-15 | 2008-02-28 | Davis Paul J | Pyrroloquinoline quinone drugs and methods of use thereof |
| US7351692B2 (en) | 2002-06-19 | 2008-04-01 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating the antipyretic action of a nonopioid analgesic |
| AU2003289440A1 (en) | 2002-12-25 | 2004-07-22 | Kissei Pharmaceutical Co., Ltd. | Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof |
| WO2005026728A1 (ja) | 2003-09-11 | 2005-03-24 | Takeda Pharmaceutical Company Limited | スクリーニング方法 |
| DE10352511A1 (de) | 2003-11-07 | 2005-06-16 | Ernst-Moritz-Arndt-Universität Greifswald | Verwendung von MRP4-Inhibitoren zur Behandlung und/oder Prophylaxe kardiovaskulärer Erkrankungen |
| CA2545944A1 (en) | 2003-11-13 | 2005-06-02 | Board Of Regents, The University Of Texas System | Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure |
| CA2555399A1 (en) | 2004-02-20 | 2005-09-01 | Novartis Ag | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
| NZ549628A (en) | 2004-03-04 | 2010-06-25 | Kissei Pharmaceutical | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs |
| CA2560005A1 (en) | 2004-03-31 | 2005-10-13 | Kissei Pharmaceutical Co., Ltd. | Phenol derivative, medicinal composition containing the same, and medicinal use thereof |
| EP2068879A2 (en) * | 2006-05-02 | 2009-06-17 | Medical Technology Acceleration Program, Inc. | Pyrroloquinoline quinone drugs and methods of use thereof |
| JP2009149534A (ja) | 2007-12-18 | 2009-07-09 | Japan Health Science Foundation | Ｔｒｐｖ２阻害剤，疾患の予防又は治療剤，薬剤探索用リード化合物，及び薬剤探索方法 |
| KR100951656B1 (ko) | 2008-02-25 | 2010-04-07 | 고려대학교 산학협력단 | 프로베네시드를 포함하는 ｔｒｐｖ２ 활성제 |
| ES2613804T3 (es) | 2008-07-17 | 2017-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibidores de MRP4 y agentes que estimulan la actividad de MRP4 para el tratamiento de trastornos cardíacos |
| US8173690B2 (en) | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| US9216171B2 (en) | 2009-05-07 | 2015-12-22 | University Of Cincinnati | Methods of preventing ischemic injury using peripheral nociceptive stimulation |
| US10806711B2 (en) * | 2011-08-12 | 2020-10-20 | University Of Cincinnati | Method of treating acute decompensated heart failure with probenecid |
-
2014
- 2014-03-13 JP JP2016502000A patent/JP2016512564A/ja active Pending
- 2014-03-13 WO PCT/US2014/025930 patent/WO2014160153A1/en not_active Ceased
- 2014-03-13 CA CA2904671A patent/CA2904671C/en active Active
- 2014-03-13 MX MX2015012547A patent/MX376077B/es active IP Right Grant
- 2014-03-13 AU AU2014244053A patent/AU2014244053B2/en active Active
- 2014-03-13 US US14/771,536 patent/US10583103B2/en active Active
- 2014-03-13 EP EP14722431.5A patent/EP2968238A1/en active Pending
-
2020
- 2020-12-08 JP JP2020203311A patent/JP2021042248A/ja active Pending
-
2023
- 2023-11-20 JP JP2023196822A patent/JP2024009140A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512564A5 (enExample) | ||
| JP2016530280A5 (enExample) | ||
| RU2016109448A (ru) | Комбинированная терапия для лечения глиобластомы | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| JP2015518818A5 (enExample) | ||
| NZ732507A (en) | Improved compositions for treating muscular dystrophy | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| WO2014198852A3 (en) | A dosing regime and formulations for type b adenoviruses | |
| RU2018123718A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| MX2019002066A (es) | Regimen de dosificacion para el tratamiento de tumores solidos. | |
| MY204827A (en) | Semaglutide in medical therapy | |
| AR104771A1 (es) | Inhalador de polvo seco | |
| JP2016515623A5 (enExample) | ||
| JP2018531605A5 (enExample) | ||
| JP2018138596A5 (enExample) | ||
| RU2019107146A (ru) | Схемы и способы лечения рассеянного склероза с применением офатумумаба | |
| HK1243704A1 (zh) | 用於在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案 | |
| MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| JP2017531042A5 (enExample) | ||
| RU2015139515A (ru) | Комбинированное лечение | |
| JP2017530142A5 (enExample) | ||
| NZ760033A (en) | Methods to treat opioid use disorder | |
| AR102903A1 (es) | Inhalador de polvo seco | |
| HK1225969A1 (zh) | 利用低剂量的拉喹莫德治疗克隆氏病 | |
| Harden | Multidrug overdose |